DUBLIN--(BUSINESS WIRE)--Sep 5, 2018--The “Bipolar Disorder Disease Coverage to 2024” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Bipolar disorder is a psychiatric disorder characterized by unusual shifts in mood, energy, activity levels, and the ability to carry out everyday tasks. Patients with the disorder may experience periods of mania (an overly joyful or overexcited state) followed by periods of depression (feelings of extreme sadness or hopelessness). Symptoms of bipolar disorder are severe and can result in damaged relationships, poor educational or occupational performance, and even suicide.
Market SnapshotTemporary downturn in bipolar market value will be recouped by oral drug approvals/launches and sales momentum of LAIs. The complexity of bipolar disorder is yet to be unlocked, contributing to a lack of episode-tailored treatment strategies. Forecasted growth in the total prevalence of bipolar I disorder and bipolar II disorder will be driven by demographics. New brand Vraylar is yet to distinguish itself, but its long patent life permits ample time to improve product positioning. Otsuka initiates Phase III development of Rexulti for bipolar mania without proof-of-concept trial.
Key Topics Covered:
Forecast: Bipolar DisorderAbilify (Aripiprazole) Abilify Maintena (Aripiprazole) Geodon (Ziprasidone) Lamictal/Lamictal Xr (Lamotrigine) Latuda (Lurasidone) Lumateperone Risperdal Consta (Risperidone) Saphris (Asenapine) Seroquel/Seroquel Xr (Quetiapine) Vraylar (Cariprazine) Zyprexa (Olanzapine)
Treatment: Bipolar DisorderPrimary Research Methodology Disease Definition And Diagnosis Patient Segmentation Current Treatment Options Treatment Dynamics Unmet Needs In Bipolar Disorder
Epidemiology: Bipolar Disorder In The US, Japan, And 5EUDisease Background Sources And Methodology Forecast: Bipolar I Disorder Forecast: Bipolar Ii Disorder Epidemiologist Insight Strengths And Limitations
Marketed Drugs: Bipolar DisorderProduct Profile: Abilify Product Profile: Abilify Maintena Product Profile: Geodon Product Profile: Lamictal Product Profile: Latuda Product Profile: Risperdal Consta Product Profile: Saphris Product Profile: Seroquel/Seroquel Xr Product Profile: Vraylar Product Profile: Zyprexa
Pipeline: Bipolar DisorderClinical Pipeline Overview Product Profile (Late Stage): Alks 3831 Product Profile (Late Stage): Rexulti Product Profile (Late Stage): Lumateperone
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/6gc3z6/global_bipolar?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180905005449/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Mental Health
INDUSTRY KEYWORD: HEALTH MENTAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/05/2018 06:45 AM/DISC: 09/05/2018 06:45 AM